Altavo GmbH is a Life Sci­ences com­pany that devel­ops pros­thet­ics based on non-inva­­sive radar sen­sor tech­nol­ogy and arti­fi­cial intel­li­gence to improve the reha­bil­i­ta­tion of voiceless

INTERCUS offers the com­plete set of implants and instru­ments for frac­ture treat­ment as well as for sur­gi­cal treat­ment of mus­culo-skele­­tal dis­eases. In addi­tion to the

The Born Group is spe­cial­ized in the sales of phar­ma­ceu­ti­cal prod­ucts via its oper­a­tive sub­sidiary Glen­wood GmbH.

In this rapidly grow­ing mar­ket for neu­rother­apy, the com­pany offers non-inva­­sive options for men­tal health, pain man­age­ment and reha­bil­i­ta­tion using neu­ro­mod­u­la­tion tech­nolo­gies inte­grated with psychotherapy.

Dy­nam­ic42 de­vel­ops, of­fers and cus­tomizes novel 3D mi­cro­phys­i­o­log­i­cal in vit­ro test sys­tems recre­at­ing hu­man or­gan key func­tions. Our hu­man in vit­ro model sys­tems en­able a

The 3D screen print­ing tech­nol­ogy of Laxxon Med­ical Corp. pro­vides phar­ma­ceu­ti­cal com­pa­nies with new, pre­vi­ously unknown pos­si­bil­i­ties for opti­mized and inno­v­a­tive drug deliv­ery sys­tems (DDS)

TrophoSYS GmbH devel­ops processes and inno­v­a­tive equip­ment in the field of biotech­nol­ogy, which pro­vide a vari­ety of solu­tions espe­cially in the field of live­stock breeding.

devie med­ical GmbH is con­cerned with the devel­op­ment, the pro­duc­tion and the sell­ing of an active sub­­s­tance-releas­ing heart valve.

Hey­fair GmbH has devel­oped a hand dis­in­fec­tion solu­tion which makes the com­plete and timely cor­rect dis­in­fec­tion vis­i­ble for 180 sec­onds through an inten­sive col­oration of the

Red­wave devel­ops the first algo­rithm for blood pres­sure cuffs that enables the deter­mi­na­tion of cen­tral blood pres­sure (in the aorta) and the mon­i­tor­ing of the

Smart­Dye­Liv­ery devel­ops patented processes to trans­port ther­a­peu­tics into the tar­get tis­sue in a highly spe­cific and effec­tive man­ner. Com­pared to con­ven­tional meth­ods, the deliv­ery of

Nova­Pump is a spe­cial­ized med­ical tech­nol­ogy com­pany based in Jena, Ger­many, which devel­ops prod­ucts for inter­ven­tional car­diac sup­port together with an exter­nal net­work and then

oncg­nos­tics devel­ops highly reli­able mol­e­c­u­lar tests based on patented epi­ge­netic mark­ers for early detec­tion, treat­ment deci­sions and fol­low-up care in can­cer diagnostics.

The goal of the com­pany is to sig­nif­i­cantly reduce today’s civilization’s dis­eases through early detec­tion and to sig­nif­i­cantly lower the asso­ci­ated high fail­ure and mortality